What Is Survodutide? A Dual GLP-1/Glucagon Agonist Built for More Than Weight Loss
Research context and evidence limits. Retatrutide references do not establish availability, comparative superiority or instructions for personal use.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide research context
Retatrutide is investigational, is not FDA-approved and cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell it. Percentages from separate trials do not establish superiority, and an average does not predict an individual outcome. The cited evidence does not establish sex-specific regimens or validate combinations with other drugs. No FDA approval date has been established.
Key Takeaways
- Survodutide is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors
- Originated at Zealand Pharma; developed and commercialized by Boehringer Ingelheim
- Phase 2 obesity data: ~19% mean body-weight reduction at 46 weeks at the highest tested dose
- Phase 3 program (SYNCHRONIZE) is ongoing across obesity, type 2 diabetes, and MASH indications
Direct answer
Survodutide is an investigational once-weekly subcutaneous peptide that activates both the GLP-1 receptor and the glucagon receptor. Boehringer Ingelheim and Zealand Pharma are co-developing it. The phase 2 obesity trial reported mean weight loss of approximately 19% at the highest dose over 46 weeks. The drug is in phase 3 trials for obesity, type 2 diabetes, and MASH liver disease. It is not yet FDA-approved.
Table of contents
- The molecule and its origins
- The unusual choice to activate glucagon
- What the phase 2 obesity trial showed
- The MASH liver story
- The SYNCHRONIZE phase 3 program
- Survodutide vs other multi-agonists
- Side-effect profile so far
- Regulatory timeline outlook
- The "survodutide peptide" search problem
- The contrary view: glucagon agonism is not without risk
- FAQ
- Sources
The molecule and its origins
Survodutide carries the development code BI 456906. The peptide originated in the Zealand Pharma research labs in Copenhagen, where the company has built a portfolio of glucagon-axis peptides over the past two decades. Boehringer Ingelheim licensed survodutide in a partnership announced in 2011 and expanded in subsequent years; Boehringer leads the global clinical development.
Zealand Pharma is also known for dasiglucagon (approved for severe hypoglycemia under the brand HypoPal/Zegalogue) and other glucagon-related compounds. Their core expertise is in modifying the glucagon and GLP-1 peptide backbones to produce molecules with custom receptor activity, half-life, and stability profiles.
Boehringer Ingelheim is a privately held German company best known in metabolic medicine for empagliflozin (Jardiance), an SGLT2 inhibitor with major cardiovascular and renal outcomes data. Survodutide represents Boehringer's first major incretin-class entry.
The unusual choice to activate glucagon
The instinctive question for many readers is: why would you want to activate glucagon, the hormone that raises blood sugar? Wouldn't that worsen diabetes?
The biology is more nuanced.
Glucagon raises glucose acutely. Released from pancreatic alpha cells during fasting, glucagon stimulates hepatic glucose production. In diabetes, excess glucagon contributes to hyperglycemia.
Glucagon also drives energy expenditure. Chronic glucagon receptor activation increases basal metabolic rate, promotes fatty acid oxidation in the liver, and reduces hepatic fat content. These effects support weight loss and improve liver fat in a way that GLP-1 alone does not.
Adding GLP-1 offsets the glucose problem. The GLP-1 component of survodutide enhances meal-stimulated insulin release and reduces glucagon secretion via central feedback. The net glycemic effect of the dual agonist, observed in trials, is improved glycemia and not worsened.
The therapeutic concept: GLP-1 controls glucose; glucagon adds energy expenditure and liver-fat reduction; combined, they produce weight loss and metabolic benefit beyond GLP-1 monotherapy.
What the phase 2 obesity trial showed
The phase 2 obesity trial (le Roux et al., Lancet 2024) randomized adults with BMI 27+ to placebo or one of three survodutide dose levels (0.6, 2.4, or 4.8 mg weekly) with structured titration over 46 weeks.
| Arm | Mean weight change (46 weeks) |
|---|---|
| Survodutide 4.8 mg | ~ -19% |
| Survodutide 2.4 mg | ~ -14% |
| Survodutide 0.6 mg | ~ -7% |
| Placebo | ~ -2% |
Note that 46 weeks is still relatively short for an obesity trial. The maximum weight loss in GLP-1 class trials typically accumulates over 60-72 weeks, with continuing slow decrease beyond 12 months. Phase 3 trials at higher doses and longer durations may produce numbers above the phase 2 result.
The MASH liver story
Survodutide's most distinctive positioning is in metabolic dysfunction-associated steatohepatitis (MASH), the new name for what was called NASH (non-alcoholic steatohepatitis). MASH is a progressive liver disease characterized by steatosis, inflammation, and varying degrees of fibrosis. It is the leading liver disease in the developed world and a major driver of liver transplantation.
The treatment landscape for MASH is sparse. Resmetirom (Rezdiffra), a thyroid hormone beta receptor agonist, was the first FDA-approved drug specifically for MASH with fibrosis in March 2024. GLP-1 monotherapy (semaglutide, in particular) has shown signal in MASH but is not yet labeled for it.
Survodutide's phase 2 MASH trial (Sanyal et al., NEJM 2024) was notable. The trial enrolled biopsy-proven MASH patients and reported substantially higher rates of histological MASH resolution and fibrosis improvement with survodutide compared to placebo over 48 weeks. The glucagon component is thought to drive direct hepatic fat reduction and improvement in steatosis beyond what would be expected from weight loss alone.
The phase 3 MASH trial is part of the broader development program. If positive, MASH could be a leading or even first indication for survodutide.
The SYNCHRONIZE phase 3 program
Boehringer Ingelheim's phase 3 obesity program for survodutide is called SYNCHRONIZE. As of mid-2025, the publicly disclosed trials include:
| Trial | Indication | Status |
|---|---|---|
| SYNCHRONIZE-1 | Obesity in adults without diabetes | Ongoing |
| SYNCHRONIZE-2 | Obesity in adults with type 2 diabetes | Ongoing |
| SYNCHRONIZE-3 | Obesity with established cardiovascular disease (CVOT) | Ongoing |
| Phase 3 MASH trial | Biopsy-confirmed MASH with fibrosis | Ongoing |
| Type 2 diabetes program | Glycemic and weight outcomes | Ongoing |
Readouts are expected in waves from 2025 through 2027. The most likely first-filing indication is obesity, with MASH and diabetes following.
Survodutide vs other multi-agonists
The investigational obesity drug landscape includes several multi-agonist molecules. The comparison:
| Drug | Receptor targets | Sponsor | Phase 2 weight loss |
|---|---|---|---|
| Survodutide | GLP-1 / glucagon | Boehringer / Zealand | ~19% at 46 weeks |
| Mazdutide | GLP-1 / glucagon | Lilly / Innovent | ~14.4% at 48 weeks (DREAMS-1, 9 mg) |
| Pemvidutide | GLP-1 / glucagon | Altimmune | ~15.6% at 48 weeks (phase 2) |
| CagriSema (combo) | GLP-1 + amylin (two molecules) | Novo Nordisk | ~22.7% at 68 weeks (phase 3) |
Survodutide sits in the middle of the GLP-1/glucagon dual-agonist class on weight loss but stands out for its MASH evidence. The MASH liver-fat reduction story may be the differentiator that defines its commercial position.
Side-effect profile so far
Phase 2 reported a GI-dominant adverse-event pattern consistent with the GLP-1 class. Notable observations from le Roux et al. 2024:
- Nausea: dose-dependent, most common in titration
- Vomiting and diarrhea: moderately common
- Heart rate increase: small mean increase
- Discontinuation for adverse events: roughly comparable to other GLP-1 class agents
- Glucagon-specific concerns: no clinically meaningful worsening of glycemia in the populations tested
The glucagon receptor activation adds theoretical concerns about hepatic effects, which the MASH program is monitoring specifically. Liver enzyme changes in phase 2 were generally favorable rather than concerning, but long-term safety in liver disease will be a central regulatory question.
Regulatory timeline outlook
A reasonable expected timeline (subject to change):
- Phase 3 obesity readouts: 2025-2026
- Phase 3 MASH readout: 2026-2027
- FDA filing for lead indication: 2026-2027
- Possible FDA approval: 2027-2028
- Commercial launch: shortly after approval, with the usual supply ramp constraints
The "survodutide peptide" search problem
"Survodutide peptide" generates substantial search volume, driven by a research-peptide gray market that has co-opted the names of investigational drugs. The pattern is familiar: a new compound appears in trials, generates press coverage, and within weeks online vendors are listing products under the same name.
What "survodutide peptide" online vendors are actually selling:
- Powdered material of variable composition, often labeled as a synthetic GLP-1/glucagon dual agonist
- Marketing language emphasizing "research use only" to disclaim medical liability
- No FDA-inspected manufacturing, no clinical formulation, no pharmacist or prescriber involvement
- Sometimes no clinical equivalent at all; sometimes a generic GLP-1 mimic relabeled with the trial drug's name
The legitimate survodutide molecule is produced under Boehringer Ingelheim's manufacturing protocols, in formulations validated for the phase 2 and phase 3 trials. That product is not commercially sold. Anyone selling "survodutide" outside of a clinical trial is, by definition, not selling the clinical drug.
The contrary view: glucagon agonism is not without risk
Adding glucagon activity to a weight-loss drug is biologically interesting but introduces concerns that GLP-1 monotherapy avoids.
Concern 1: Glycemic destabilization. In non-diabetic patients, sustained glucagon activation could theoretically raise fasting glucose. The phase 2 trials did not show this, but long-term effects in diverse populations are not yet established.
Concern 2: Hepatic and cardiovascular signals. Glucagon receptor activation in the liver has complex effects on lipid metabolism. The MASH data is favorable, but signals in patients without baseline liver disease could differ.
Concern 3: Lean mass loss. All effective obesity drugs produce lean mass loss alongside fat loss. Whether glucagon-driven increased energy expenditure preserves or worsens lean mass at the population level is an open question.
None of these concerns negate the trial benefit. They are reasons to interpret the early data carefully and to expect that survodutide's labeling and post-market surveillance will be active questions for years.
Decision framework
If you have obesity and qualify for current therapy: Wegovy, Zepbound, and other approved drugs are available now. Waiting for survodutide does not make sense unless you have a specific reason (MASH, for instance) to prefer this mechanism.
If you have MASH: resmetirom is approved; semaglutide is being studied for MASH but is not labeled for it. Survodutide's phase 3 MASH data, when it reads out, may inform a clinical decision. Talk to a hepatologist about clinical trial enrollment if you have biopsy-confirmed MASH.
If you have established cardiovascular disease and obesity: the SELECT-style data favors semaglutide for now. Survodutide CV outcomes data is still developing.
If you're considering a "research peptide" version of survodutide: don't. The product is not legitimate, the quality is unverifiable, and the legal exposure is real.
FAQ
How do you pronounce survodutide?
Approximately "sur-vo-DOO-tide." The "tide" ending is shared with most of the GLP-1 class names.
Is survodutide a triple agonist?
Is survodutide better than tirzepatide?
No head-to-head trial exists. Cross-trial estimates suggest tirzepatide may produce more weight loss in obesity; survodutide may have a unique edge in MASH.
Will survodutide be approved for MASH first or for obesity first?
Obesity is the more advanced program; the MASH indication may follow. Boehringer has not formally announced filing order.
Is survodutide available now?
No. It is investigational. The only legitimate access is clinical trial enrollment.
Will my insurance cover survodutide?
Coverage decisions cannot be made for a drug that is not yet approved. After launch, coverage will follow typical patterns for new obesity biologics, with several months to a year of formulary lag.
Does survodutide cause hypoglycemia?
Phase 2 did not show clinically significant hypoglycemia in non-diabetic populations. Patients on insulin or sulfonylureas may need dose adjustment if survodutide is approved for diabetes.
Is survodutide oral?
No. It is a once-weekly subcutaneous injection.
Can I take survodutide and tirzepatide together?
No. There is no clinical scenario where combining incretin-class drugs is appropriate. Doing so would predictably stack side effects without proven added benefit.
Related guides
- Survodutide for MASH: How a Dual Agonist Targets the Liver
- Survodutide for MASH: Boehringer's Dual Agonist, Closer Look
- Why Is Glucagon Activation Good for Weight Loss
Sources
- le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet. 2024.
- Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and liver fibrosis. New England Journal of Medicine. 2024.
- Boehringer Ingelheim. Survodutide Pipeline Disclosure and SYNCHRONIZE Program Materials. 2024-2025.
- Zealand Pharma Annual Report 2024. BI 456906 milestone disclosures.
- Harrison SA et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine. 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
- Jastreboff AM et al. Tirzepatide for Obesity (SURMOUNT-1). NEJM. 2022.
- Loomba R et al. Semaglutide 2.4 mg in NASH (semaglutide MASH trials). Hepatology. 2024.
- American Association for the Study of Liver Diseases. Practice Guidance on MASH. 2024.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
- FDA. Guidance for Industry: NASH/MASH Drug Development. 2023.
Footer disclaimers
Investigational Drug Notice. Survodutide is investigational and not approved by the FDA. As of May 2026 it is in phase 3 trials. The only legitimate pre-approval access is enrollment in a registered clinical trial. Online "survodutide" research peptides are not the clinical drug.
Results Disclaimer. Trial weight-loss percentages reported here are group means from phase 2 data in controlled settings with structured lifestyle support. Phase 3 outcomes may differ. Individual response varies and is not predictable from population averages.